Side-by-side · Research reference
PinealonvsTeriparatide
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AHuman-MechanisticAUTO-DRAFTED12/36 cited
BFDA-ApprovedHUMAN-REVIEWED10/62 cited
Pinealon
Pineal-derived · Neuroprotective
SQ or IM · Daily for 10 days · 1-2×/year
Teriparatide
PTH (1-34) Fragment · FDA-Approved
SQ · Thigh/Abdomen · Once Daily
01Mechanism of Action
Parameter
Pinealon
Teriparatide
Primary target
Antioxidant defense + neuronal gene expression (proposed)Khavinson 2014
Parathyroid hormone 1 receptor (PTH1R) on osteoblastsXue 2026
Pathway
Modulation of antioxidant enzymes (SOD, catalase) + neurotrophic factor expressionKhavinson 2014
PTH1R activation → cAMP/PKA signaling → osteoblast differentiation and activity
Downstream effect
Reduced oxidative stress in neurons; improved cognitive function in age-related declineKhavinson 2014
Stimulates osteoblast formation and bone matrix deposition; increases bone mineral density at trabecular and cortical sites
Feedback intact?
—
Yes — intermittent dosing preserves anabolic effect; continuous exposure causes catabolic bone resorption
Origin
Synthetic 4-AA peptide derived from pineal gland extractKhavinson 2014
Recombinant 34-amino-acid N-terminal fragment of 84-amino-acid human PTH
Antibody development
—
—
02Dosage Protocols
Parameter
Pinealon
Teriparatide
Frequency
Once daily during cycle
Once daily
Intermittent administration preserves anabolic effect.
Lower / starter dose
2.5 mg / day
—
Duration
10-day cycles, 1–2× per year
—
Reconstitution
Bacteriostatic water
—
Timing
No specific time
Morning or evening (flexible)
Half-life
Hours
—
Standard dose (osteoporosis)
—
20 mcg / day
FDA-approved regimen for severe osteoporosis.
Maximum duration
—
24 months lifetime
Anabolic effect wanes after 12-18 months; FDA recommends max 2-year cumulative exposure.
Hypoparathyroidism dose
—
20 mcg / day
Used off-label for chronic hypoparathyroidism.
Pelvic fragility fractures
—
20 mcg / day × 8-12 weeks
Accelerates fracture healing; reduces time to union.Crooks 2026
Route
—
Subcutaneous (thigh or abdomen)
Storage
—
Refrigerate 2-8 °C; pen device stable at room temp for 28 days after first use
Pharmacogenetics
—
ALDH2 polymorphisms may influence BMD responseObara 2026
ALDH2*2 variant carriers show altered PTH receptor expression.Obara 2026
03Metabolic / Fat Loss Evidence
Parameter
Pinealon
Teriparatide
Fat loss application
—
None — teriparatide is a bone anabolic agent without direct lipolytic activity
04Side Effects & Safety
Parameter
Pinealon
Teriparatide
Injection site reaction
Mild irritation
Erythema, bruising, pain (uncommon)
Long-term safety
Limited Western data
—
Pregnancy / OB
Avoid
—
Hypercalcemia
—
Transient serum calcium elevation 4-6 hours post-injection
Monitor serum calcium; usually asymptomatic.
Orthostatic hypotension
—
Dizziness, lightheadedness within hours of injection
Nausea
—
Common, usually mild and transient
Leg cramps / Arthralgia
—
Musculoskeletal pain reported in clinical trials
Hypercalciuria
—
Increased urinary calcium excretion; monitor for nephrolithiasis risk
Osteosarcoma (black box warning)
—
Rat studies showed dose-dependent osteosarcoma; not observed in humans to date; contraindicated in Paget's disease, skeletal malignancy, prior radiation
Absolute Contraindications
Pinealon
- ·Pregnancy / breastfeeding
Teriparatide
- ·Paget's disease of bone (increased baseline osteosarcoma risk)
- ·Unexplained elevated alkaline phosphatase
- ·Prior skeletal radiation therapy
- ·Skeletal malignancies or bone metastases
- ·Hypercalcemic disorders (primary hyperparathyroidism)
- ·Pregnancy / lactation
Relative Contraindications
Pinealon
- ·Active malignancy (theoretical via gene expression modulation)
Teriparatide
- ·Active or recent nephrolithiasis
- ·Severe renal impairment (CKD G4-G5)
- ·Hypercalciuria without adequate monitoring
05Administration Protocol
Parameter
Pinealon
Teriparatide
1. Reconstitution
Add 1–2 mL bacteriostatic water to 10 mg vial.
Teriparatide is supplied in pre-filled pen injectors (Forteo pen). Store refrigerated at 2-8 °C until first use. After first injection, pen may be kept at room temperature for up to 28 days. Do not freeze.
2. Injection site
SQ — abdomen preferred.
Subcutaneous injection into thigh or lower abdomen. Rotate sites daily to avoid lipodystrophy. Avoid areas with scars, bruises, or active skin conditions.
3. Timing
Daily during cycle, any time.
Once daily, at approximately the same time each day. Morning or evening administration is acceptable. Take while sitting or lying down to minimize orthostatic hypotension risk.
4. Storage
Lyophilised: room temp. Reconstituted: refrigerate ≤30 days.
Clean injection site with alcohol swab. Pinch skin, insert needle at 90° angle, and inject full dose (20 mcg). Hold for 5 seconds before withdrawing needle. Do not rub injection site.
5. Needle
29–31G, 4–8 mm insulin syringe.
Baseline and periodic monitoring of serum calcium, urinary calcium, serum PTH (if hypoparathyroidism), and bone mineral density (DXA scan). Monitor for hypercalcemia 4-6 hours post-dose if symptomatic.
6. Calcium and vitamin D supplementation
—
Ensure adequate calcium (1000-1200 mg/day) and vitamin D (800-1000 IU/day) intake unless contraindicated by hypercalcemia or hypercalciuria.
06Stack Synergy
Pinealon
+ Epitalon
ModeratePinealon (neuroprotection) + Epitalon (telomerase activation) form the canonical Khavinson "longevity stack" — both pineal-derived bioregulators with complementary axes. Pinealon supports neuronal antioxidant defense; Epitalon supports telomere maintenance. Anecdotally cycled together 1–2× per year.
- Pinealon
- 5–10 mg SQ · daily × 10 days
- Epitalon
- 5–10 mg SQ · daily × 10 days (overlap or alternate)
- Primary benefit
- Neuroprotection + telomere preservation
Teriparatide
— no documented stacks